This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
by Zacks Equity Research
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
PFENegative Net Change MRNANegative Net Change ARCTPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
by Zacks Equity Research
Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.
MRNANegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
by Zacks Equity Research
Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
ANIPNegative Net Change KRYSNegative Net Change SAVANegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
by Zacks Equity Research
Data from a late-stage study shows that AbbVie's tavapadon reduced the burden of Parkinson's disease. The drug previously demonstrated efficacy as adjunctive therapy.
ABBVNegative Net Change ADMANegative Net Change KRYSNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
by Zacks Equity Research
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
BMYPositive Net Change ABBVNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
by Zacks Equity Research
Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.
ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change BMEANegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
BIIBNegative Net Change VNDANegative Net Change WVEPositive Net Change BHVNNegative Net Change ZVRANegative Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
by Zacks Equity Research
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
PFENegative Net Change ADMANegative Net Change KRYSNegative Net Change BVSNegative Net Change
biotechs medical pharmaceuticals
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
by Zacks Equity Research
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
REGNNegative Net Change SNYNegative Net Change AMGNNegative Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study
by Zacks Equity Research
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.
CLDXNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals
by Zacks Equity Research
RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.
RHHBYNegative Net Change ANIPNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
TSVT, BMY Discontinue Enrollment in Late-stage Abecma Study
by Zacks Equity Research
2seventy bio and partner BMY decide to stop enrollment in the late-stage study on Abecma due to growth in the newly diagnosed multiple myeloma treatment space.
REGNNegative Net Change BMYPositive Net Change NVONegative Net Change TSVTNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
by Zacks Equity Research
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
GSKNegative Net Change NVSNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
by Zacks Equity Research
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
AZNPositive Net Change GSKNegative Net Change BIIBNegative Net Change ANIPNegative Net Change
biotechs
Eli Lilly Secures Approval for Alzheimer's Drug Kisunla in Japan
by Zacks Equity Research
Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in July 2024.
BIIBNegative Net Change LLYNegative Net Change PRTANegative Net Change SAVANegative Net Change
biotechs medical pharmaceuticals
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
by Zacks Equity Research
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
ANIPNegative Net Change WVEPositive Net Change KRYSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
REGNNegative Net Change RHHBYNegative Net Change AMGNNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
by Zacks Equity Research
The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.
ANIPNegative Net Change BHVNNegative Net Change KRYSNegative Net Change FULCPositive Net Change
biotechs
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
by Zacks Equity Research
Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
SNYNegative Net Change NVONegative Net Change LLYNegative Net Change VTYXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
by Zacks Equity Research
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change
biotechnology biotechs pharmaceuticals
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
by Zacks Equity Research
APLS stock falls as the CHMP confirms its June 2024 negative opinion on the regulatory filing for intravitreal pegcetacoplan to treat GA in the EU.
ILMNNegative Net Change KRYSNegative Net Change APLSNegative Net Change FULCPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change CRBPNegative Net Change
biotechnology biotechs medical pharmaceuticals
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.
AZNPositive Net Change PFENegative Net Change MRKPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
by Zacks Equity Research
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
REGNNegative Net Change SNYNegative Net Change BMYPositive Net Change JNJNegative Net Change
biotechs medical pharmaceuticals
Longboard Stock Soars on FDA Designations for Epilepsy Drug
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
ILMNNegative Net Change KRYSNegative Net Change BVSNegative Net Change LBPHPositive Net Change
biotechs medical